Literature DB >> 9193789

Adenosine A3 receptor agonists inhibit murine macrophage tumor necrosis factor-alpha production in vitro and in vivo.

T L Bowlin1, D R Borcherding, C K Edwards, C D McWhinney.   

Abstract

Adenosine and related analogs have been shown to regulate a variety of cell functions through different classes of adenosine receptors. Murine J774.1 macrophage cells were found to predominantly express adenosine A3 receptor RNA relative to adenosine A1 receptor or adenosine A2 receptor RNA. Adenosine receptor agonists, in a dose-dependent manner characteristic of the adenosine A3 receptor, blocked endotoxin-induction of the TNF-alpha gene and TNF-alpha protein expression in the J774.1 macrophage cell line. The adenosine A3 receptor antagonist BW-1433 dose-dependently reversed this adenosine receptor agonist inhibitory effect on TNF-alpha gene expression. Thus, the binding of adenosine receptor agonists to the adenosine A3 receptor interrupts the endotoxin CD14 receptor signal transduction pathway and blocks induction of cytokine TNF-alpha, revealing a novel cross-talk between the murine adenosine A3 receptor and the endotoxin CD14 receptor in J774.1 macrophages.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9193789

Source DB:  PubMed          Journal:  Cell Mol Biol (Noisy-le-grand)        ISSN: 0145-5680            Impact factor:   1.770


  10 in total

1.  Cyclic AMP-dependent inhibition of human neutrophil oxidative activity by substituted 2-propynylcyclohexyl adenosine A(2A) receptor agonists.

Authors:  G W Sullivan; J M Rieger; W M Scheld; T L Macdonald; J Linden
Journal:  Br J Pharmacol       Date:  2001-03       Impact factor: 8.739

Review 2.  Present concepts on the inflammatory modulators with special reference to cytokines.

Authors:  A S J P A M Van Miert
Journal:  Vet Res Commun       Date:  2002-02       Impact factor: 2.459

3.  Chapter 13. A3 Adenosine Receptors.

Authors:  Kenneth A Jacobson; Susanna Tchilibon; Bhalchandra V Joshi; Zhan-Guo Gao
Journal:  Annu Rep Med Chem       Date:  2003       Impact factor: 1.059

Review 4.  Adenosine and adenosine receptors in the pathogenesis and treatment of rheumatic diseases.

Authors:  Bruce N Cronstein; Michail Sitkovsky
Journal:  Nat Rev Rheumatol       Date:  2016-11-10       Impact factor: 20.543

5.  A3 adenosine receptor agonist reduces brain ischemic injury and inhibits inflammatory cell migration in rats.

Authors:  In-Young Choi; Jae-Chul Lee; Chung Ju; Sunyoung Hwang; Geum-Sil Cho; Hyuk Woo Lee; Won Jun Choi; Lak Shin Jeong; Won-Ki Kim
Journal:  Am J Pathol       Date:  2011-08-18       Impact factor: 4.307

6.  Adenosine reduces cell surface expression of toll-like receptor 4 and inflammation in response to lipopolysaccharide and matrix products.

Authors:  Benjamin Haas; Frederique Leonard; Isabelle Ernens; Sophie Rodius; Melanie Vausort; Magali Rolland-Turner; Yvan Devaux; Daniel R Wagner
Journal:  J Cardiovasc Transl Res       Date:  2011-05-03       Impact factor: 4.132

Review 7.  Adenosine and ischemic preconditioning.

Authors:  B T Liang; K A Jacobson
Journal:  Curr Pharm Des       Date:  1999-12       Impact factor: 3.116

Review 8.  Regulation of atherosclerosis and associated risk factors by adenosine and adenosine receptors.

Authors:  Milka Koupenova; Hillary Johnston-Cox; Katya Ravid
Journal:  Curr Atheroscler Rep       Date:  2012-10       Impact factor: 5.113

Review 9.  New clinical applications of xanthine derivatives: modulatory actions on leukocyte survival and function.

Authors:  K Yasui; A Komiyama
Journal:  Int J Hematol       Date:  2001-01       Impact factor: 2.319

10.  Inhibition of primary colon carcinoma growth and liver metastasis by the A3 adenosine receptor agonist CF101.

Authors:  G Ohana; S Bar-Yehuda; A Arich; L Madi; Z Dreznick; L Rath-Wolfson; D Silberman; G Slosman; P Fishman
Journal:  Br J Cancer       Date:  2003-10-20       Impact factor: 7.640

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.